EP1113802B1 — Antiviral combinations of lamivudine and adefovir
Assigned to Glaxo Group Ltd · Expires 2004-06-30 · 22y expired
What this patent protects
The present invention relates to therapeutic combinations comprising (2R, cis) -4-amino-1- (2-hydroxymethyl-1, 3-oxathiolan-5-yl) -pyrimidin-2-one (lamivudine) and a second therapeutic agent selected from (9-[(R) -2-(phosphonomethoxy) ethyl]adenine, (PMEA or adefovir) and bis(piv…
USPTO Abstract
The present invention relates to therapeutic combinations comprising (2R, cis) -4-amino-1- (2-hydroxymethyl-1, 3-oxathiolan-5-yl) -pyrimidin-2-one (lamivudine) and a second therapeutic agent selected from (9-[(R) -2-(phosphonomethoxy) ethyl]adenine, (PMEA or adefovir) and bis(pivaloyloxymethyl) (9-[(R) -2- (phosphonomethoxy)ethyl]adenine, (the oral prodrug of PMEA, adefovir dipivoxil) w hich have anti-hepatitis B virus (HBV) activity. The present invention is also concerned with pharmaceutical compositions containing said combinations and their use in the treatment of HBV infections including infections with HBV mutants bearing resistance to nucleoside and/or non-nucleoside inhibitors.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.